FULCRUM THERAPEUTICS INC. - COMMON STOCK

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

01 May 2025 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

24 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Apr 2025 16:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

04 Mar 2025 16:05:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

25 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

18 Feb 2025 16:05:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Feb 2025 16:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

06 Feb 2025 16:05:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate in Upcoming December Conferences

26 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024

13 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

12 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

06 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Oct 2024 16:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Sep 2024 16:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

12 Sep 2024 06:55:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate in Upcoming September Conferences

27 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

23 Aug 2024 16:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

19 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 Aug 2024 16:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024

31 Jul 2024 07:00:00 By Nasdaq GlobeNewswire